RSS
3 Sep 2022

Yingli Pharma Announces First Patient Dosed in Phase 2 Trial of Linperlisib for Peripheral T Cell Lymphoma

Author: admintech | Filed under: Press Release

Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma SAN FRANCISCO, Sept. 3, 2022 /PRNewswire/ — Yingli Pharma (the “Company” or “Yingli”), a clinical stage biotechnology company developing oral small molecule drugs…

This entry was posted on Saturday, September 3rd, 2022 at 7:15 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»